New Scientist reports that researchers have tested an ALS gene therapy in a mouse model of disease.
The assay was shown to have a simpler workflow and was able to detect mosaicism, with only a slight decrease in sensitivity compared to a lab-developed test.
The New York Genome Center created MetroNome as a way to show genomic data in the context of phenotypes, but integration challenges lie ahead.
Silicon Valley VC firm DFJ led the investment in Verge, which is applying machine learning to the development of new drugs for Parkinson's and ALS.
Using large-scale GWAS data, researchers saw shared genetic contributors for ALS and frontotemporal dementia, as well as ALS and progressive supranuclear palsy.
Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.
Both a genome-wide association study and a rare variant burden analysis homed in on a role for KIF5A mutations in amyotrophic lateral sclerosis.
Gizmodo wonders whether CRISPR could present a treatment for amyotrophic lateral sclerosis.
In Science this week: genomic studies of how fungal pathogen overcomes resistant wheat plants, and more.
The partners will integrate genomic, imaging, and other data to identify new therapies and personalize treatments for patients with neurological and neurodegenerative diseases.
Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.
Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.
A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.
In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.